So the first type is to base a retinal vein occlusion based on the parts of the retina that it's involving. So you can have something called a central retinal vein occlusion, and that's where you ...

Central retinal vein occlusion (CRVO) is a common retinal vascular disorder with potential risk of blindness. CRVO can be categorized into two distinct entities – non-ischemic and ischemic.

Brown GC, Magargal LE, Shields JA, et al. Retinal arterial obstruction in children and young adults. Ophthalmology 1981;88:18–25. Rosenberg MA, Savino PJ, Glaser JS . A clinical analysis of ...

The global retinal vein occlusion (RVO) market, valued at US$ 2.8 billion in 2023, is poised for substantial growth over the ...

QUASAR is a global, double-masked, active-controlled phase 3 trial evaluating the efficacy and safety of EYLEA HD, compared ...

OBJECTIVES: To determine whether a chorioretinal venous anastomosis could be created in humans and to evaluate the influence this has on patients with nonischemic central retinal vein occlusions ...

In the QUASAR trial, the efficacy and safety of Eylea HD were compared to Eylea in treatment-naïve patients with macular edema secondary to retinal vein occlusion including central retinal vein ...

Regeneron Pharmaceuticals REGN announced that it has met the primary endpoint in a late-stage study evaluating Eylea HD ...

Bayer announces positive results from phase III QUASAR study of aflibercept 8 mg in patients with macular edema following retinal vein occlusion: Berlin Thursday, December 19, 202 ...

Regeneron (NASDAQ:REGN) announced Tuesday that Eylea HD, the high-dose version of its blockbuster eye care medication Eylea ...

Approximately 90% of aflibercept 8 mg patients were extended to every 8-week dosing and maintained their interval through 36 weeks ...